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Running Title: Analysis of linezolid and tigecycline in bone cement 15 
 16 
Objective: To assess the use of Gram-positive specific antibiotic linezolid and the broad-17 
spectrum antibiotic tigecycline, for use in local antibiotic delivery via antibiotic-loaded bone 18 
cement. 19 
 20 
Methods: Linezolid and tigecycline were added to Biomet bone cement at varying 21 
concentrations. Antibiotic elution over one week was quantified by HPLC-MS. The effect of 22 
wear on elution over 48 h was determined using a modified TE-66 wear tester. Eluted 23 
antibiotics were used to determine MIC against a panel of clinically relevant bacteria. Impact 24 
strength of antibiotic-loaded samples was determined using a Charpy-type impact testing 25 
apparatus. Cytotoxicity of eluted antibiotics against MG-63 cells was evaluated using an 26 
MTT assay.  27 
 28 
Results: Linezolid and tigecycline eluted from bone cement to clinically relevant levels 29 
within 1 hour and retained activity over 1 week. Mechanical wear significantly reduced 30 
elution of tigecycline but had little effect on elution of linezolid. Linezolid showed low 31 
cytotoxicity towards MG-63 cells with  300 mg/mL resulting in >50 % cell activity. 32 
Cytotoxicity of tigecycline was higher, with an IC50 of 5-10 mg/L.  33 
 34 
Conclusions: Linezolid and tigecycline retain activity after elution from bone cement. The 35 
concentration of tigecycline may need to be carefully controlled due to cytotoxicity. The 36 
effect of wear on bone cement may need to be considered if tigecycline is to be used for local 37 
delivery. Up to 10% linezolid can be added without affecting the impact strength of the bone 38 
cement. These results are promising indications for future investigation of these antibiotics 39 
toward use in local antibiotic delivery strategies. 40 
 41 
Introduction 42 
 43 
Prosthetic joint infections present a rare but major complication in arthroplastic surgery. The 44 
incidence of infection across all arthroplastic procedures has been reported as ranging from 1 45 
– 3%.1-3 Revision surgery to remedy an infected joint prosthesis is associated with increased 46 
costs, longer stay in hospital and potential morbidity, compared to revision surgery after 47 
aseptic failure.4-6 The number of arthroplastic procedures and the incidence of infection have 48 
increased over the last 10 years, as have the total costs associated with revision surgery.4,5,7 49 
As the demand for arthroplastic surgery progressively rises, the costs associated with 50 
prosthetic joint infection are set to increase greatly. This has led to perioperative antibiotic 51 
prophylaxis strategies including the use of antibiotic-loaded bone cement becoming 52 
routine.8,9 53 
 54 
The management of a prosthetic joint infection involves removal of the infected prosthesis 55 
and radical debridement of the surrounding infected tissue. This is followed by either a one-56 
stage revision where a new prosthesis is implanted in a single procedure or a two-stage 57 
revision where a temporary spacer is used for several weeks before the new prosthesis is 58 
implanted. In both procedures antibiotic therapy is standard practice, commonly combining 59 
systemic antibiotic treatment with local delivery using antibiotic-loaded bone cement. 60 
Antibiotic-loaded cement is used to cement the prosthesis into place and, in the two-stage 61 
revision, is used to form the temporary spacer.10 62 
 63 
Antibiotic-resistant organisms such as methicillin-, vancomycin- and multidrug resistant 64 
strains are increasingly becoming associated with failure of revision surgery. More than 50% 65 
of all prosthetic joint infections are caused by staphylococci such as Staphylococcus aureus 66 
and Staphylococcus epidermidis and it has been estimated that around half of all S. aureus-67 
related  periprosthetic joint infections are now methicillin resistant.1,11-13 The ability of these 68 
organisms to acquire antibiotic resistance requires the use of new antibiotics to be explored 69 
for use in bone cement. 70 
 71 
Here we evaluate linezolid and tigecycline for use in antibiotic-loaded bone cement systems 72 
and assess their suitability for this application. There are few studies investigating the 73 
inclusion of linezolid in bone cement14,15 and, to our knowledge, there are no published data 74 
on the inclusion of tigecycline in bone cement. Linezolid is a member of the oxazolidinone 75 
family of antibiotics and is active against most Gram positive organisms including many 76 
drug-resistant strains.16 Tigecycline is a member of the glycylcycline family of antibiotics 77 
and has good activity against both Gram negative and Gram positive organisms.17 78 
 79 
Materials and methods 80 
 81 
Bacterial strains and growth conditions 82 
 83 
All strains were maintained on Mueller-Hinton agar or Mueller-Hinton broth and grown 84 
overnight at 37°C. Clinical isolates of S. aureus, S. epidermidis and Escherichia coli were 85 
isolated from infected prostheses at the Northern General Hospital, Sheffield. S. epidermidis 86 
DSM 3269 was purchased from the Deutsche Sammlung von Mikroorganismen und 87 
Zellkulturen (DSMZ, Braunschweig, Germany). The S. aureus strain SH1000 was provided 88 
by Simon Foster, University of Sheffield. 89 
  90 
Antimicrobial susceptibility 91 
 92 
Serial dilutions of antibiotic standard solutions or serial dilutions of buffer from antibiotic 93 
elution experiments were prepared in triplicate with fresh Mueller Hinton broth in 96 94 
microtitre well plates. Wells were inoculated with each microorganism in triplicate to a final 95 
density of 105 cfu/mL and incubated overnight at 37˚C. MICs were determined by eye and 96 
were defined as the lowest concentration of antibiotic that showed complete inhibition of 97 
growth. 98 
 99 
MG63 cell culture 100 
 101 
Cells were cultured on Eagles minimal essential medium (EMEM) containing 10 % fetal 102 
bovine serum (v/v), 2 mM glutamine and 1 % non-essential amino acids (v/v). Cells were 103 
incubated at 37˚C (5 % CO2) and passaged three times a week. 104 
 105 
MTT assay 106 
 107 
MG63 cells were seeded at 2 × 103 cells per well in 100 µL of EMEM containing the 108 
appropriate concentration of antibiotic. Cells were incubated at 37˚C (5 % CO2) for 48 h. 109 
After 48 h the medium was removed and fresh medium added. A 12 mM stock solution of 110 
MTT was prepared and 10 µL added to each well before incubating at 37˚C (5 % CO2) for 4 111 
h. An SDS-HCl (100 mg/mL, 0.01M HCl) stock solution was prepared and 100 µL added to 112 
each well before incubating for a further 4 h. Absorbance was measured at 570 nm and 113 
compared to positive control cultures containing no antibiotic. 114 
 115 
Preparation of bone cement 116 
 117 
Linezolid, tigecycline and gentamicin-containing bone cement samples were prepared by 118 
hand-mixing antibiotic powder (3% or 10% wt/wt) with Biomet Bone Cement R® powder 119 
until a homogenous mix was produced. The antibiotic cement powder was then mixed with 120 
the appropriate amount of polymethylmethacrylate (PMMA) monomer liquid in a Hi-Vac 121 
bone cement mixing bowl (Biomet) as per the manufacturer’s instructions. Refobacin Bone 122 
Cement R® and Bone cement R (Biomet) were also prepared in a Hi-Vac bone cement 123 
mixing bowl (Biomet) as per the manufacturer’s instructions. The bone cement was placed 124 
into the relevant mould and allowed to cure for 1 hour. Once removed from the mould,  125 
antibiotic-loaded cement samples were stored at -20°C for up to 1 week until required in 126 
order to preserve antibiotic activity. The storage of bone cement at this temperature was 127 
shown to have no appreciable effect on elution of antibiotic (data not shown). 128 
 129 
Static elution of antibiotic from bone cement samples 130 
 131 
Antibiotic-loaded bone cement was placed in circular moulds and allowed to cure for 1 h to 132 
produce a 31 mm diameter x 7 mm thick disc. The resulting bone cement discs were then 133 
placed in 0.1 M ammonium acetate (pH 7.4) solution stirred at 300 rpm in a UV-opaque 134 
container and 0.5 mL aliquots of solution taken over 1 week and stored at -20 °C until 135 
analysed.   136 
 137 
Evaluation of the effect of wear on antibiotic elution 138 
 139 
Evaluation of the effect of wear on the rate of elution of antibiotics from the bone cement was 140 
carried out via a procedure based on that described by Dodds et al.,18 as follows. The 141 
antibiotic-loaded bone cement was formed in an annulus-shaped mould and a 2 kg weight 142 
placed on top. The resulting annular samples were 40 mm outer diameter, 8 mm inner 143 
diameter and 10 mm thick. The sides of the annulus were coated with beeswax to ensure 144 
antibiotic could only elute from the outer perimeter. Controlled wear was generated by use of 145 
a HVOF-VPD hydroxyapatite (HA) coated 30 mm diameter x 3 mm thick Ti disc which was 146 
placed onto the lever arm specimen holder of a TE-66 microabrasive wear tester.16 The 147 
sample was orientated so that the flat 10 mm thick outer perimeter was in contact with the 148 
HA-coated counter-face and a 2.5 N force exerted by the counter-face onto the outer 149 
perimeter of the wearing cement sample. A container was placed beneath the assembly and 150 
filled with 0.1 M ammonium acetate solution (pH 7.4) until the lower portion of the cement 151 
sample was submerged. A magnetic stirrer was used to mix the solution in the container at 152 
300 rpm and samples were rotated against the HA counter-face at 60 rpm for 51 h. The HA 153 
counter-face was repositioned every 10 - 12 h to ensure a sufficiently abrasive counter-face 154 
throughout the experiment.  An extension shaft was fitted to the TE-66 to allow simultaneous 155 
rotation of an unworn control sample at the same speed. This sample was also partially 156 
submerged in a separate container filled with 0.1M ammonium acetate solution (pH 7.4). The 157 
experiment was placed in a UV-sealed air-tight container and the temperature and humidity 158 
constantly measured during the experiment. At regular intervals, 200 µL aliquots of solution 159 
were taken and stored at -20°C before analysis. 160 
 161 
Quantification of antibiotics by LC-MS 162 
 163 
Detection of linezolid was carried out on a Phenomenex Luna C18 reversed phase column 164 
(150 mm x 1 mm) attached to a Finnigan LCQ ESI-MS. The isocratic mobile phase was 0.1% 165 
aqueous trifluoroacetic acid (TFA)/acetonitrile (77:23) and the flow rate was 0.05 mL/min. 166 
Measurement of linezolid concentration was carried out by monitoring the protonated parent 167 
ion at m/z 338.2 and comparing the results to a standard curve. Quantification of tigecycline 168 
was carried out as described above except the isocratic mobile phase was 0.1% aqueous 169 
TFA/methanol (67:33) and monitoring the protonated parent ion at m/z 586.5. 170 
 171 
  172 
Impact strength analysis 173 
 174 
The impact testing was carried out as described by Barker et al.19 using a Charpy-type impact 175 
tester (Hounsfield Plastics impact testing apparatus). Antibiotic-loaded bone cement was 176 
moulded into 44.45mm × 7.93mm × 7.93mm bars and notched using the Hounsfield notching 177 
machine (notch tip radius 0.25mm). Impact analysis was carried out according to BS ISO 178 
179-1:2010 specifications20 with the exception of the specimen dimensions. For each sample 179 
group 5 specimens were made and force applied to the un-notched side.  180 
 181 
Statistical analysis 182 
 183 
Statistical comparison of wear and non-wear samples was carried out by unpaired t-test. The 184 
statistical analysis of impact testing samples was carried out by one way analysis of variance.  185 
All statistical analysis was carried out using  Microsoft Excel software 186 
 187 
Results 188 
 189 
Elution of antibiotic from bone cement 190 
 191 
Elution of antibiotic from bone cement samples containing 3% (wt/wt) linezolid or 3% 192 
(wt/wt) tigecycline was monitored over a 1-week period. The concentration of linezolid 193 
eluted from the bone cement increased over the 1 week time period of the experiment (Fig 1). 194 
A maximum concentration of 12.2 ± 2.9 mg/L of linezolid was reached after 168 h and the 195 
initial elution rate of linezolid from bone cement was calculated as 213.4 ± 33.4 µg/hour/g 196 
bone cement. The concentration of eluted tigecycline initially increased to a maximum 197 
concentration of 0.66 ± 0.35 mg/L after one hour and then decreased to 0.084 ± 0.025 mg/L  198 
after 24 h and 0.014 mg/L ± 0.013 after 168 h (Fig 2). The initial elution rate of tigecycline 199 
from bone cement was calculated as 32.8 ± 17.2 µg/hour/g bone cement. 200 
 201 
Effect of wear on elution of bone cement 202 
 203 
The results from three separate experiments to investigate the effect of wear on elution 204 
behaviour of cement containing 3 % (wt/wt) tigecycline are shown in Fig. 3. The samples 205 
were collected over a 51 h period and the maximum concentration of eluted antibiotic was 206 
reached between 5 h and 12 h. The highest concentration overall was seen in the unworn 207 
sample 2 after 12 h with a concentration of 2.1 mg/L compared to 0.1 mg/L in the worn 208 
counterpart (Fig 3b). Although there is some variability in the maximum concentrations 209 
between the three experiments, in all cases a clear trend can be seen with the elution from 210 
unworn samples being significantly higher than the worn bone cement samples (P < 0.05).  211 
After 1 hour the elution of tigecycline from unworn samples was 9.4 ± 2.6 µg/hour/cm3 212 
surface and the rate of elution from the worn samples was 2.3 ± 2.5 µg/hour/cm3 surface. 213 
 214 
The results from three separate experiments to investigate the effect of wear on elution 215 
behaviour of cement containing 3 % (wt/wt) linezolid are shown in Fig. 4. The samples were 216 
collected over a 51 h period and the maximum concentration of eluted antibiotic was reached 217 
between 24 h and 51 h with concentration continuing to increase in all but one sample. The 218 
highest concentration overall was seen in the worn sample 2 after 51 h with a concentration 219 
of 53.1 mg/L (Fig 4b). No significant difference can be seen in the elution kinetics between 220 
the worn and unworn linezolid samples (P = 0.63).  After 1 hour the rate of elution from 221 
 
  
 
 
  
unworn linezolid samples was 232.5 ± 22.4 µg/hour/cm3 surface and the rate of elution from 222 
the worn linezolid samples was 242.4 ± 24.3µg/hour/cm3 surface. The rates of antibiotic 223 
elution from both unworn and worn linezolid samples were > 100-fold higher than that of the 224 
worn tigecycline samples and 24.8 and 25.9-fold higher respectively than the unworn 225 
tigecycline samples. 226 
Antimicrobial activity of eluted antibiotics 227 
S. aureus (SH1000), S. epidermidis (DSM 3269) and an S. epidermidis strain isolated from an 228 
infected prosthesis were used as test organisms to investigate whether the eluted antibiotics 229 
retained antimicrobial activity.  The MICs of these strains with standard solutions of the 230 
antibiotics are shown in Table S1 in the Supplementary material. Concentration of linezolid 231 
and tigecycline eluted at various times from antibiotic-loaded cement samples were 232 
determined via LC-MS and the MICs of the eluted antibiotics were determined 233 
experimentally (Tables 1 and 2). All eluted tigecycline samples showed activity comparable 234 
with the standard solution and established breakpoints21,22 for all organisms tested (Table 1).  235 
The linezolid samples eluted up to 72 h all showed activity comparable to determined MICs 236 
and breakpoints against the Gram positive organisms.21 The linezolid samples eluted over 1 237 
week (168 h) showed higher MICs compared to the other samples and the Gram negative E. 238 
coli was not inhibited by any of the linezolid samples, as expected (Table 2). 239 
Cytotoxicity of antibiotics towards MG63 cells 240 
The cytotoxic effects of standard solutions of linezolid and tigecycline against MG63 cells 241 
were determined using the MTT assay. The addition of increasing concentrations of 242 
tigecycline resulted in a marked reduction in cell activity with an IC50 between 5 – 10 mg/L. 243 
The addition of linezolid showed a small reduction in activity that was not statistically 244 
significant (P > 0.05). Up to 300 mg/L of linezolid resulted in < 50% reduction in cell activity 245 
and so an IC50 for linezolid could not be determined (Supplementary material Fig S1).  246 
Comparing these results to the concentrations achieved in the elution experiments (Figures 1-247 
4), it is possible that cellular toxicity of tigecycline may be an issue if the in vivo eluted 248 
concentrations are comparable to those in this laboratory system, whereas linezolid did not 249 
show toxicity to mammalian cells, even at substantially higher concentrations than those 250 
achieved in the elution experiments. 251 
Impact testing to assess physical strength of bone cements samples 252 
A Charpy type impact test machine was used to evaluate the impact strength of the antibiotic 253 
loaded bone cement. Separate bone cement samples loaded either with tigecycline or 254 
linezolid at 3 % and 10 % wt/wt were tested, and the results compared to both bone cement 255 
without antibiotic and a commercially prepared gentamicin-loaded bone cement, Refobacin® 256 
Bone Cement R (Table 3). There was no significant difference in the impact strength of the 257 
tigecycline-loaded cement samples at either concentration, compared to the control without 258 
antibiotic. The 10% (wt/wt) tigecycline-loaded cement was the only cement that had an 259 
impact strength that appeared slightly lower than the bone cement without antibiotic, 260 
however that difference was not statistically significant. Further, there was no significant 261 
difference between the linezolid-loaded samples at either concentration and the Refobacin® 262 
Bone cement R samples (P > 0.05). The impact strength of both the 3% and 10% (wt/wt) 263 
tigecycline cement samples were significantly less (P < 0.05) than, though still comparable 264 
to, the commercially available Refobacin® Bone Cement R.   265 
 266 
 267 
Discussion 268 
 269 
The results presented here indicate that tigecycline and linezolid can be included within bone 270 
cement and that the elevated temperatures that occur during the curing stage do not 271 
compromise their antimicrobial and biocompatibility properties. Both antibiotics elute to 272 
clinically relevant concentrations within the first hour in our laboratory elution system (Fig 1 273 
and 2) and retain antimicrobial activity up to one week later. The concentrations of eluted 274 
tigecycline peaked around 1 h (Fig 2) and then declined, presumably due to decomposition of 275 
the antibiotic.  The MICs for eluted tigecycline based upon the concentrations measured by 276 
LC-MS showed results comparable with those determined using standard antibiotic solutions 277 
(Table 1; Supplementary material Table S1). The MICs of eluted linezolid, the concentration 278 
of which increased progressively throughout the experiment (Fig 1), were comparable with 279 
those determined using standard antibiotic solutions over the first 72 h. After 1 week, eluted 280 
linezolid showed approximately 5-20-fold higher MICs than the standard linezolid (Table 2; 281 
Supplementary material Table S1) , which may indicate slow decomposition of the eluted 282 
antibiotic that was not revealed by LC-MS. Previously, Anagnostakos et al. reported elution 283 
of 1%  of total linezolid from bone cement, compared to 3% for gentamicin loaded cement 284 
over 8 days and Jackson et al. reported up to 3% elution over a 4 week period.14,15  Cement 285 
containing linezolid and gentamicin has shown inhibited growth of methicillin-resistant 286 
S.aureus for up to 8 days.14 However as this previous study is in conjunction with gentamicin 287 
it does not necessarily confirm the activity of the linezolid on its own.  288 
 289 
The effect of wear on the tigecycline-loaded bone cement samples significantly reduces the 290 
elution of tigecycline. After 1 hour there was > 4-fold reduction in the elution rate from the 291 
worn sample, compared to the unworn control (Fig 3). Conversely, wear has very little effect 292 
on the elution of linezolid from the bone with similar elution rates and profiles for both worn 293 
and unworn samples (Fig 4). This may be relevant in the clinical application of these systems 294 
where the cement surface experiences wear. Previously we have reported similarly 295 
contrasting results with gentamicin and daptomycin–loaded bone cements where elution of 296 
gentamicin was significantly reduced by wear, yet elution of daptomycin was not affected.16 297 
In this study it was suggested that crystal size and distribution were the two main factors 298 
influencing this difference in elution characteristics between the two antibiotics. It was 299 
observed that the larger crystals of gentamicin within the orthopaedic cement created voids 300 
on the surface upon contact with the aqueous solution, thus allowing greater deformation of 301 
the bone cement surface due to wear. It was further proposed that this deformation prevented 302 
the solution from penetrating deep into the bone cement, thereby limiting the amount of 303 
antibiotic that can be eluted. In the current study we have shown that the crystals of 304 
tigecycline are smaller than the linezolid crystals and so crystal size appears not to be the 305 
main factor determining the reduced elution from worn bone cement samples here 306 
(Supplementary material Fig S1). However there is a much greater tendency for the 307 
tigecycline crystals to aggregate within the cement compared to the linezolid. The surface of 308 
the tigecycline loaded cement showed areas of aggregated tigecycline crystals, which may 309 
also produce voids upon contact with the aqueous solution and so increase the deformation of 310 
the bone cement surface (Supplementary material Fig S2, S3). 311 
 312 
The impact strength of the linezolid and tigecycline loaded cements produced results 313 
comparable to those commercially available bone cements. The lowest impact strength was 314 
seen in the 10% tigecycline containing cement suggesting that tigecycline may have some 315 
effect on the mechanical strength of the cement. A previous study by Kries et al showed the 316 
addition of tigecycline had a detrimental effect on compressive and bending strength of 317 
tigecycline-loaded bone cement.23 Kries et al. also mentioned a 3.8-fold increase in curing 318 
time compared to cement only. Curing time was not specifically investigated during the 319 
current study, but all cement samples were fully cured within < 1 h.  320 
 321 
The MTT assay showed that linezolid had low cytotoxicity towards MG63 cells. Up to 300 322 
mg/L linezolid concentration resulted in <50% loss of cell activity and so an IC50 was not 323 
determined. Tigecycline showed greater cytotoxicity with an IC50 of 5 - 10 mg/L. This result 324 
is consistent with the findings of Pina et al.,24 who also found that tigecycline concentrations 325 
>10 mg/L severely affected the cell growth of osteoblastic cells. 326 
 327 
Conclusions 328 
 329 
The antimicrobial activity of linezolid and tigecycline eluted from within bone cement, 330 
reaches therapeutically relevant concentrations within the critical perioperative period (based 331 
on a typical arthroplasty operation of 1-2 h). Antimicrobial activity is observed up to 1 week 332 
later. However, the concentration of tigecycline added to cement may need to be controlled 333 
due to the possible cytotoxicity of the eluted antibiotic towards osteoblast cells. The effect of 334 
wear in reducing elution of tigecycline in the laboratory reported here is also a factor to be 335 
borne in mind if this antibiotic is used in revision surgery. Owing to ongoing antibiotic 336 
resistance problems, there is a need to use antibiotics such as linezolid and tigecycline both 337 
alone and in conjunction with other antibiotics (such as gentamicin which is included in 338 
commercial bone cement preparations currently widely used in arthroplasty surgery). The 339 
current study is an in vitro assessment of the performance and do not model the conditions in 340 
vivo. Upon implantation the prosthetic comes into contact with extracellular fluid, bone and 341 
muscle tissue, all of which will affect elution and the local accumulation of antibiotic. Further 342 
work assessing the in vivo performance of these cements as well as more mechanical testing 343 
needs to be carried out to fully evaluate these antibiotic loaded cements. However, based on 344 
the results presented above we propose that linezolid and tigecycline are encouraging 345 
candidates for local delivery via antibiotic loaded bone cement, in the treatment and 346 
prevention of prosthetic joint infection.  347 
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Fig 1: Concentration of linezolid eluted from bone cement over a 1-week period. Results are shown as the 
mean of three separate experiments ± standard deviation and have been normalised to 1 g bone cement in 
5 mL of buffer. 
Fig 2: Concentration of tigecycline eluted from bone cement over a 1 week period. Results are shown as 
the mean of three separate experiments ± standard deviation and have been normalised to 1 g bone cement 
in 5 mL of buffer. 
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Fig 3) Results from three separate experiments (A, B and C) comparing elution of tigecycline 
from worn and unworn tigecycline-loaded bone cement. Concentration of antibiotic was 
quantified by LCMS. 
 
 
    
 
   
A)  
B) 
C) 
 
  
    
    432 
 433 
 434 
 435 
  436 
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Fig 4) Results from three separate experiments (A, B and C) comparing elution of linezolid 
from worn and unworn linezolid-loaded bone cement. Concentration of antibiotic was 
quantified by LCMS. 
C) 
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Organism 1 h 
eluate 
(mg/L) 
24 h 
eluate 
(mg/L) 
48 h 
eluate 
(mg/L) 
72 h 
eluate 
(mg/L) 
168 h 
eluate 
(mg/L) 
      
S.aureus SH1000 0.2 0.1 0.059 0.088 0.044 
Methicillin-resistant 
S.aureus (clinical isolate) 
<0.10 0.056 0.059 0.088 0.044 
S.epidermidis (clinical 
isolate) 
0.41 0.225 0.12 0.18 >0.18 
S.epidermidis (DSM 
3269) 
0.41 0.28 0.12 0.088 0.052 
E.coli (clinical isolate) 0.41 0.7 0.24 0.35 >0.18 
 438 
Table 1:MICs of tigecycline eluted from bone cement, determined by the broth microdilution method. 439 
Experiments were carried out in triplicate.  440 
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Organism 1h 
eluate 
(mg/L) 
24 h 
eluate 
(mg/L) 
48 h 
eluate 
(mg/L) 
72 h 
eluate 
(mg/L) 
168 h 
eluate 
(mg/L) 
      
S.aureus SH1000 1.9 0.89 0.93 1.06 9.75 
Methicillin-resistant 
S.aureus (clinical 
isolate) 
1.9 0.89 0.93 1.06 9.75 
S.epidermidis (clinical 
isolate) 
0.95 0.89 0.93/1.88 0.53 9.75 
S.epidermidis (DSM 
3269) 
0.95 0.89 0.93 0.53 9.75 
E.coli (clinical isolate) >15.27 >28.50 >30.00 >34.00 >9.75 
 451 
Table 2: MICs of linezolid eluted from bone cement, determined by the broth microdilution method. 452 
Experiments were carried out in triplicate..  453 
  454 
 455 
Bone cement  1. Impact 
strength 
(kJ.m2)  
 
Cement only  0.259 ± 0.0444  
3% tigecycline  0.2649 ± 0.0299 
10% tigecycline  0.2271 ± 0.0217  
3% linezolid  0.3175 ± 0.0422  
10% linezolid  0.3187 ± 0.0493  
3% gentamicin  0.3205 ± 0.05 
10% gentamicin 0.3673 ± 0.0133 
Refobacin®  Bone Cement R 
(1.25 % gentamicin)  
0.3343 ± 0.0212  
Table 3: Impact strength of antibiotic loaded bone cements determined using a Charpy-type testing apparatus. 456 
Results are shown as a mean of five separate experiments ± standard deviation. Biomet Bone Cement® was used 457 
for all preparations unless stated otherwise. 458 
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